Observational Study ‘Usefulness of Ivermectin in COVID-19 Illness’ Raises some Questions

Observational Study ‘Usefulness of Ivermectin in COVID-19 Illness’ Raises some Questions

Recently, a TrialSite News reader shared an interesting but not peer-reviewed, nor formally published study that we republish for others to review and scrutinize. The authors, Amit N. Patel, MD; Sapan S. Desai, MD, PhD, MBA; David W. Grainger, PhD; and Mandeep R. Mehra, MD, MSc, introduce a retrospective observational study as to the benefits of the drug ivermectin when applied to patients infected with SARS-CoV-2, the virus behind the COVID-19 epidemic. Upon a review of the paper, it is not clear where the actual underlying data originates from. TrialSite News includes the study abstract (with a link to the actual study) and offers a summary breakdown below. 

TrialSite News includes an assessment of this study from a popular YouTube channel.

Who are the authors?

Amit N. Patel is associated with the University of Utah, Department of Bio-engineering and HCA Research Institute in Florida. Sapan S. Desai, MD, PhD, MBA, is employed by Surgisphere Corporation in Chicago, IL. David W. Grainer, PhD, is with the University of Utah, Department of Bio-engineering. Mandeep R. Mehra, MD, MSc is affiliated with 4Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medica...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee